Premium
Nm23‐H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: univariate and multivariate analysis
Author(s) -
Marioni Gino,
Ottaviano Giancarlo,
Lionello Marco,
Lora Lucia,
Lovato Andrea,
Staffieri Claudia,
Favaretto Niccolò,
Giacomelli Luciano,
Stellini Edoardo,
Staffieri Alberto,
Blandamura Stella
Publication year - 2012
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2012.04331.x
Subject(s) - multivariate analysis , univariate analysis , medicine , hazard ratio , univariate , multivariate statistics , gastroenterology , oncology , carcinoma , proportional hazards model , pathology , confidence interval , statistics , mathematics
Marioni G, Ottaviano G, Lionello M, Lora L, Lovato A, Staffieri C, Favaretto N, Giacomelli L, Stellini E, Staffieri A & Blandamura S
(2012) Histopathology
Nm23‐H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: univariate and multivariate analysis Aims: To use image analysis and multivariate analysis to investigate the prognostic significance of Nm23‐H1 subcellular localization in a large cohort of laryngeal squamous cell carcinomas (LSCCs). Methods and results: Nm23‐H1 total and nuclear levels were immunohistochemically determined and calculated with an image analysis system in 104 consecutively operated LSCCs. The mean follow‐up was 58.3 ± 35.1 months (median 45 months). Total Nm23‐H1 levels correlated only with patient stratification by pT ( P = 0.01). Mean nuclear Nm23‐H1 levels were lower in patients with recurrent disease ( P = 0.01), and disease‐free survival (DFS) was longer in patients whose nuclear levels of Nm23‐H1 were >2.0% than in those with levels ≤2.0% ( P = 0.019). On multivariate analysis, Nm23‐H1 nuclear expression [hazard ratio (HR) 2.59, P = 0.005] and N stage (HR 3.60, P = 0.0001) were prognostically significant in relation to DFS. Conclusions: In LSCC, Nm23‐H1 nuclear expression may be useful for identifying patients at higher risk of recurrence after treatment and who might be considered for more aggressive therapy. Further investigations are needed before Nm23‐H1 can be considered for use in targeted treatments for LSCC.